Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report

T. Pokrivcak, J. Navratil, A. Poprach, M. Stanik, I. Kiss

. 2024 ; 17 (1) : 537-542. [pub] 20240404

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu kazuistiky

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013063

INTRODUCTION: Prostate cancer is one of the most common cancers in men. Despite the sharp rise in incidence, mortality is decreasing. ARTA preparations are preferred options for asymptomatic or mildly symptomatic patients with mCRPC. The use of enzalutamide in elderly patients with mCRPC is risky and depends on a number of factors. An increased risk of falls and fractures has been shown. CASE PRESENTATION: We present a case report of an elderly patient with mCRPC treated with enzalutamide with very good long-term tolerance and efficacy. CONCLUSION: Despite the older age, no reduction of therapy was necessary in the patient due to good tolerance. Administration of enzalutamide in full doses resulted in a very good effect of therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013063
003      
CZ-PrNML
005      
20240903092416.0
007      
ta
008      
240723s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000538124 $2 doi
035    __
$a (PubMed)38577248
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Pokrivcak, Tomas $u Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report / $c T. Pokrivcak, J. Navratil, A. Poprach, M. Stanik, I. Kiss
520    9_
$a INTRODUCTION: Prostate cancer is one of the most common cancers in men. Despite the sharp rise in incidence, mortality is decreasing. ARTA preparations are preferred options for asymptomatic or mildly symptomatic patients with mCRPC. The use of enzalutamide in elderly patients with mCRPC is risky and depends on a number of factors. An increased risk of falls and fractures has been shown. CASE PRESENTATION: We present a case report of an elderly patient with mCRPC treated with enzalutamide with very good long-term tolerance and efficacy. CONCLUSION: Despite the older age, no reduction of therapy was necessary in the patient due to good tolerance. Administration of enzalutamide in full doses resulted in a very good effect of therapy.
590    __
$a NEINDEXOVÁNO
655    _2
$a kazuistiky $7 D002363
700    1_
$a Navrátil, Jiří $u Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0164164
700    1_
$a Poprach, Alexandr $u Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Stanik, Michal $u Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kiss, Igor $u Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00173224 $t Case reports in oncology $x 1662-6575 $g Roč. 17, č. 1 (2024), s. 537-542
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38577248 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240903092413 $b ABA008
999    __
$a ok $b bmc $g 2125586 $s 1224926
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 17 $c 1 $d 537-542 $e 20240404 $i 1662-6575 $m Case reports in oncology $n Case Rep Oncol $x MED00173224
LZP    __
$a Pubmed-20240723

Najít záznam

Citační ukazatele

Možnosti archivace